Bora expands its CDMO capabilities, buying TWi Pharma

13 September 2022

Fast-growing contract development and manufacturing organization (CDMO), Bora Pharmaceuticals (TWO: 64720, has completed the acquisition of fellow Taiwan based TWi Pharmaceutical, a technology-based company specializing in development and commercialization of niche generic drugs. Financial terms were not disclosed.

Acquiring TWi Pharmaceuticals adds two manufacturing facilities and will significantly boost Bora’s service offerings in key areas, such as formulation development, sterile ophthalmic, and niche manufacturing technologies.

In May this year, Bora Pharmaceuticals acquired the CDMO assets from local player, Eden Biologics, to help it build a presence in large-molecule contract drug development and manufacturing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK